Inhibition of matrix metalloproteinase activity by TIMP-1 gene transfer effectively treats ischemic cardiomyopathy

Circulation

Volumn 110, Issue 11 SUPPL., 2004, Pages

  Jayasankar, Vasant ^a   Woo, Y Joseph ^a   Bish, Lawrence T ^a   Pirolli, Timothy J ^c   Berry, Mark F ^a   Burdick, Jeffrey ^a   Bhalla, Ramesh C ^b   Sharma, Ram V ^b   Gardner, Timothy J ^a   Sweeney, H Lee ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c 6 Silverstein Pavilion ^*

Author keywords

Gene therapy; Heart failure; Metalloproteinases; Remodeling

Indexed keywords

HYDROXYPROLINE; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY LIGATION; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; EXPERIMENTAL MODEL; GENE TRANSFER; GEOMETRY; HEART FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; ISCHEMIC HEART DISEASE; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ADENOVIRIDAE; ANIMALS; DEFECTIVE VIRUSES; DRUG EVALUATION, PRECLINICAL; FIBROSIS; GENE THERAPY; GENES, SYNTHETIC; GENETIC VECTORS; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HUMANS; HYDROXYPROLINE; LIGATION; MALE; MATRIX METALLOPROTEINASES; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, INBRED LEW; RECOMBINANT FUSION PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 4644329326     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000138946.29375.49     Document Type: Article

References (29)

1. Nelson AR, Fingleton B, Rathenberg ML, et al. Matrix metalloproteinases: biological activity and clinical implications. J Clin Oncol. 2000; 18:1135-1149.
2. Cleutjens JPM, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol. 1994;27:1281-1292.
3. Li YY, Feldman AM, Sun Y, et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation. 1998;98:1728-1734.
4. Fedak PWM, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol. 2003;284:H626-H634.
5. Bril A, Percevault-Albadine J, Landais L, et al. Ventricular remodeling and tolerance to ischemia in rabbits with myocardial infarction. J Mol Cell Cardiol. 1994;26:322-330.
6. Romanic AM, Burns-Kurtis CL, Gout B, et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sciences. 2001;68:799-814.
7. Gunja-Smith Z, Morales AR, Romanelli R, et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996;148: 1639-1648.
8. Spinale FG, Coker ML, Thomas CV, et al. Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res. 1998;82:482-495.
9. Anversa P, Ricci R, and Olivetti G. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review. J Am Coll Cardiol. 1986;7:1140-1149.
10. Muhs BE, Patel S, Yee H et al. Inhibition of matrix metalloproteinases reduces local and distant injury following experimental acute pancreatitis. J Surg Res. 2003;109:110-117.
11. De Hingh IH, Siemonsma MA, de Man BM et al. The matrix metalloproteinase inhibitor BB-94 improves the strength of intestinal anastomoses in the rat. Int J Colorectal Dis. 2002;17:348-354.
12. Garcia C, Bartsch DU, Rivero ME, et al. Efficacy of Prinomastat (AG3340), a matrix metalloproteinase inhibitor in treatment of retinal neovascularization. Curr Eye Res. 2002;24:33-38.
13. Spinale FG, Coker ML, Krombach SR, et al. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res. 1999;85:364-376.
14. King MK, Coker ML, Goldberg A, et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003;92:177-185.
15. Drummond AH, Beckett P, Brown PD, et al. Preclinical and clinical studies of MMP inhibitors in cancer. NY Acad Sci. 1999;878:228-235.
16. Levitt NC, Eskens FALM, O'Byrne KJ, et al. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MM 1270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res. 2001;7:1912-1922.
17. Docherty AJ, Lyons A, Smith BJ, et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 1985;318:66-69.
18. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 1999;19:2871-2877.
19. Liu YH, Yang XP, Nass O, et al. Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol. 1997;272: H722-H727.
20. Jayasankar V, Woo YJ, Bish LT, et al. Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure. Circulation. 2003; 108:II230-II236.
21. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
22. Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14:2123-2133.
23. Creemers EJM, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Heart Circ Physiol. 2003;284:H364-H371.
24. Kim HE, Dalal SS, Young E, et al. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest. 2000;106: 857-866.
25. Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000;106:55-62.
26. Heymans S, Luttun A, Nuyens G, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med. 1999;5: 1135-1142.
27. Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res. 2000;46:307-315.
28. Simeon A, Monier F, Emonard H, et al. Fibroblast-cytokine-extracellular matrix interactions in wound repair. Curr Top Pathol. 1999;93:95-101.
29. Kato S, Spinale FG, Tanaka R, et al. Inhibition of collagen cross-linking: effects on fibrillar collagen and left ventricular diastolic function. Am J Physiol. 1995;269:H863-H868.